Trevena (NASDAQ:TRVN) Now Covered by StockNews.com

Investment analysts at StockNews.com started coverage on shares of Trevena (NASDAQ:TRVNGet Free Report) in a research report issued to clients and investors on Wednesday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reissued a “neutral” rating and set a $5.00 target price on shares of Trevena in a research note on Thursday, November 14th.

Check Out Our Latest Stock Analysis on TRVN

Trevena Price Performance

Shares of TRVN stock opened at $1.61 on Wednesday. Trevena has a one year low of $1.13 and a one year high of $19.23. The company’s fifty day moving average price is $2.38 and its 200-day moving average price is $5.12. The company has a market capitalization of $1.38 million, a price-to-earnings ratio of -0.03 and a beta of 1.08.

Trevena (NASDAQ:TRVNGet Free Report) last posted its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($5.79) EPS for the quarter. The business had revenue of $0.28 million during the quarter. Equities research analysts expect that Trevena will post -23.04 earnings per share for the current fiscal year.

Trevena Company Profile

(Get Free Report)

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.

Read More

Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.